Clinical

Dataset Information

0

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations


ABSTRACT: The purpose of this study is to evaluate the efficacy and safety of selinexor alone or with pembrolizumab in participants with advanced or metastatic colorectal cancer (CRC). Approximately 78 participants with advanced or metastatic CRC will be enrolled, and randomized (1:1:1) into three arms A (selinexor only), B (selinexor and pembrolizumab), and C (standard of care [Combination of trifluridine and tipiracil]). Randomization will be based on stratification factors: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 versus 2. The end of treatment (EoT) visit will occur less than or equal to (<=30) days post-treatment discontinuation. A survival follow-up visit will be performed every 3 months from EoT and will continue for 12 months.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2375040 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2022-03-14 | GSE158765 | GEO
2021-09-09 | GSE183415 | GEO
| PRJNA670936 | ENA
2018-01-30 | GSE109792 | GEO
2024-03-08 | GSE250241 | GEO
| PRJNA486155 | ENA
2016-06-11 | E-GEOD-83233 | biostudies-arrayexpress
2023-08-30 | GSE240184 | GEO
2013-02-25 | E-GEOD-44271 | biostudies-arrayexpress
2019-05-07 | GSE130748 | GEO